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A b s t r A c t
Invasive fungal infection is one of the major complication of severe burns which can induce local or systemic inflammatory response 
and cause serious substantial damage to the patient. The incidence of fungal infection for burn victims is increasing dramatically 
during recent years. This guideline, organized by Chinese Society of Burn Surgeons, aims to standardize the diagnosis, prevention 
and treatment of burn invasive fungal infection. It can be used as one of the tools for treatment of major burn patients.
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Introduction 
Presently, more and more cases of  invasive fungal 
infections are found post-burn, especially after severe burn 
injury.[1-3] Factors associated with invasive fungal infection 
after burn injury include administration of  broad-
spectrum antibiotics, tracheostomy tubing, mechanical 
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ventilation, parenteral nutrition and invasive monitoring. 
The increasing rate of  nosocomial infections in China 
may also be another associated factor;[4-6] the increased 
rate of  reporting of  fungal infections has also resulted 
from the development of  improved diagnostic techniques 
for fungal infections and increased awareness among 
medical staffs.[7,8] The aim of  this guideline, developed 
by Chinese Society of  Burn Surgeons, is to standardize 
the diagnosis, prevention and treatment of  invasive fungal 
infection after burn injury in China. The guideline is 
based on consensus opinion of  27 doctors and experts 
from 18 hospitals and burn centers all over China. This 
version includes 4 parts: The concept, the diagnosis, the 
prophylaxis and the treatment of  burn invasive fungal 
infection (BIFI).
Concept of the BIFI
Invasive fungal infection after burn injury is termed as BIFI. 
BIFI is characterized by local or systemic inflammation, 
tissue and cell damage caused by colonization, growth and 
proliferation of  various fungi in wounds, blood stream, 
internal organs, or tissues of  burn patients.
Diagnosis of burn invasive fungal infection
There are 5 clinical features that symbolize BIFI: Host 
susceptibility, clinical manifestation, fungi detection, 
histological examination, and imaging and laboratory 
results.[2,9,10]
Host susceptibility[12]
a. The mechanical barrier severed by intact human skin 
is destroyed after burn injury, enabling fungi and other 
microorganisms to invade easily. In addition, necrotic 
or degenerated tissues are favorable culture medium for 
colonization and growth of  various microorganisms 
including fungi. Furthermore, immune dysfunction is 
almost always induced after severe burn injury, with the 
resultant immunosuppression favoring fungi and other 
microbial infections.[12-14]
b. Patients at increased risk of  BIFI include the elderly, 
children, and the patients with concomitant chronic 
illness associated with immunosuppression, e.g. diabetes 
and autoimmune illnesses.[15,16]
c. Broad-spectrum antibiotics, commonly administered to 
patients after severe burns injury, are an additional risk 
factor for BIFI.[17]
d. Severe burn patients combined with inhalation injury, 
who should always apply tracheostomy tubing and 
continuous mechanical ventilation for long term.[18]
e. Long term use of  invasive monitoring, deep venous 
catheter, and intravenous parenteral nutrition support.[19]
f. The severe burn patients always had a long-term stay in 
hospital.[20,21]




a. Temperature: Most of  the patients suffer continuous 
fever, usually above 39-40°C. A few patients manifest 
remittent fever. Hypothermia is frequently associated 
with advanced or fulminant infections.
b. Consciousness: Systemic infection is associated with 
altered conscious states, with rapid changes commonly 
observed. The consciousness alteration can display excita-
tion or inhibitory patterns such as delirium, restlessness, 
babbing, lethargy, apathy, staring spells, and so forth.
c. Respiration system: Dyspnea is commonly observed 
secondary to the septic process or respiratory infections. 
The sputum appears gelatinous when the patient has 
invasive fungal infection in lungs.
d. Digestive system: Poor appetite, nausea, anorexia and 
abdominal distention are common complaints. Dys-
phagia and odynophagia are common with abnormal 
bowel actions appearing watery or mucoid. Pediatric 
patients are often found to have oral mucosal ulcers and 
pseudo-tunica albuginea.
e. Urinary system: The urine may become cloudy. In cases 
of  urethritis, dysuria, frequency and urgency have been 
observed.
f. Circulation: Tacchycardia may be induced by hyperther-
mia. Arrhythmia may be associated with myocardial 
infection. Hypotension signifies fulminant disease.
g. Others: Microabscesses can occur when fungi dissemi-
nate through blood stream to lung, liver, kidney, spleen, 
brain, blood vessels, eyes and other internal organs.
Appearance of  the burn wound[26]
a. Round or irregularly shaped brown or black mildew or 
ecthyma gangrenosa can be found on wound crust.
b. Wound deepens with bean dregs-like or cheese-like 
necrosis rapidly and progressively. Infection of  mucor 
often leads to embolism formation with resultant 
progressive necrosis in muscle or extremities.
c. Inflammation around wounds infected with fungi are 
obvious. Granulation tissue looks gray or bright red but 
is fragile and bleeds easily. Mucoidal exudate frequently 
covers the wound. Skin graft appears patent initially but 
is unable to grow or expand. Hematogenous spread of  
Aspergillus and Mucor leads to extensive skin hemor-
rhage or necrosis. Hemorrhagic spots and disseminated 
erythematous nodules may be found on normal skin.
Effect of  antibiotics treatment
If  presumed to be a bacterial infection and following treat-
ment with antibiotics for 3-5 days, the general symptoms 
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and local appearances do not change or recur with worsen-
ing severity.
Fungus detection
Microscopic examination of  fungus[27,28]
The diagnosis is established by hyphae found under micro-
scope continuously two times in one kind of  sample or in 
more than two kinds of  different samples such as wound 
exudate, respiratory secretions, urine, or stool. Hyphae may 
be present in irrigating solution of  bronchoalveolar lavage. 
Pityrosporion ovale cyst, trophont, or intracapsule are found 
in sputum or bronchoalveolar lavage douche.
Culture of  fungus[27]
The diagnosis may also be made by a type of  fungus iso-
lated and identified from at least 2 samples such as wound 
exudate, respiratory secretions, urine, blood, and others. 
The same fungus should be cultured continuously two 
times from one kind of  sample. The fungi are cultured and 
presented in concentrations of  more than 106 and 104 colony 
forming unit (CFU)/ml in sputum or bronchoalveolar 
lavage fluid or 105 CFU/ml and 105 CFU/g for urine or 
stool sample, respectively.
Histological evidence[29,31]
Diagnosis by histological evidence for burn wound in-
volves the detection of  hyphae in wound biopsy sections, 
especially fungi around blood vessels, or period acid-schiff  
(PAS) staining positive in unburnt tissues. The histologi-
cal diagnosis is the gold standard to burn wound invasive 
fungal infection.
Imaging and laboratory examination
a. Imaging: Persistence of pulmonary signs of consolida-
tion or new lesions after antibiotics treatment should 
alert the clinician to the possibility of BIFI. Signs of 
pulmonary infection with Candida displays as nodular 
consolidation or/and large consolidation but seldom 
with cavitation. When infected by Aspergillus, hy-
perdense consolidation with different shapes can be 
found under the pleura. Halo signs are usually found 
around the lesions. A few days later the consolidation 
field undergoes liquefaction or necrosis, with the forma-
tion of hollow shadow or air-crescent signs. Following 
hematogenous spread, widespread miliary shade can 
be found disseminating all over the fields.[32-34]
b. Blood routine examination: The proportion of  neutro-
phil is below the lower limit of  normal value or with 
sudden descent.[35]
c. G test: G test is to detect fungus cell wall ingredient 
1,3-β-D glycans by enzyme-linked immunosorbent assay 
(ELISA). In BIFI, G test displays positive from blood 
sample for 2 times continuously.[36,37]
d. GM test: Galactomannan (GM) assay by ELISA shows 
optic density is more than 0.8 for 2 times continuously 
or more than 1.5 in one time from blood or respiratory 
secretion samples.[38,39]
e. Polymerase chain reaction (PCR) test: Specific positive 
bands are amplified with the specific primers for 
the fungal 18S transfer ribonucleic acid (tRNA) and 
ribosomal deoxyribonucleic acid (rDNA).[40,41]
Diagnostic classification
The diagnosis of BIFI can be divided into 3 grades, i.e. proven 
diagnosis, probable diagnosis and possible diagnosis.
a. Proven diagnosis: Diagnosis of  BIFI can be proven once 
any of  the following three terms is met: Histological 
evidence is present; besides host susceptive factors 
and clinical manifestation with microorganism 
identified; besides host susceptive factors and clinical 
manifestation, with at least 2 imaging or laboratory 
signs, as described above.
b. Probable diagnosis: There is no histological or fungal 
microorganism evidence. Besides host susceptive factors 
and clinical manifestation with only one imaging or 
laboratory test positive.
c. Possible diagnosis: Only host susceptibility factors and 
clinical manifestation are present with no histological, 
fungal microorganism, or imaging and laboratory 
examination evidence [Table 1].
Diagnosis of  fungal infections of  burn wounds from bac-
terial infection is difficult, mostly reliably made by histo-
logical examination of  burn wound tissue samples along 
with culture of  the biopsy sample. The bacterial infection 
can release a large amount of  endotoxin into the blood, 
Table 1: Diagnostic classification of invasive fungal infection after burn injury
Classification Histological evidence Host susceptive factors Clinical manifestation Fungus detection Imaging and laboratory examination
Proven
+ ± ± ± ±
— + + + ±
— + + — At least two in five items positive
Probable — + + — Only one in five items positive
Possible — + + — —
+: Positive, ±: Positive or negative, —: No evidence
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 accompanying the sepsis symptoms. The number of bacteria 
present around the wound area can be more than 105/g with 
vasculitis or perivascular inflammation symptoms.
Prophylaxis of BIFI
Prophylaxis[42]
Wound should be nursed clean and dry and be allowed to 
drain completely. Moreover, long-term compression dress-
ing should be avoided. Open wounds should be covered 
and closed as soon as possible.[24]
Antibiotics should be applied rationally. Broad-spectrum 
antibiotics should be avoided for long period and focused to 
culture results as soon as possible.[43]
The use of  indwelling catheters should be minimized as far 
as practicable. If  inevitable, these should be nursed carefully. 
The indwelling time and date should be marked. Invasive 
arterial and venous lines should be checked and nursed 
twice a day; the indwelling sites should be changed every 
5-7 days for the routine catheter. If  the catheter is indwelled 
on burn wound, the site should be checked and nursed 4 
times a day and maintained clean and dry.[44-46]
Tracheal intubation and mechanical ventilation should be 
avoided and the period should be shortened if  possible. The 
incision site should be cleaned, disinfected, and dressing 
changed for 1-2 times every day and for 3-4 times a day if  
it has to go through burn wound. It should be strengthened 
of  respiratory tract management and nursing including 
sputum aspiration in time, humidification, and other 
measurements.[24]
Hypoxic ischemic injury of  digestive tract should be 
prevented and treated in time during early stage after burn 
injury with early enteral feeding and prevention of  intestinal 
flora imbalance. For patients with definite host susceptive 
factors, ecologic agents such as Bifidobacterium and/or 
Bacillus subtilis are advised to be given from day 3 after burn 
injury to maintain the intestinal flora balance and inhibit 
invasive fungal infection from intestinal tract.[47-49]
Metabolic disorders should be treated and corrected in time. 
Enteral with or without parenteral nutrition support is necessary 
to meet the need of the metabolism of the severe burn patients.
The treatment of  any basic diseases such as diabetes im-
mune hypofunction disease, chronic lung disease, and others 
should be enhanced. Glucocorticoid and other immunosup-
pressants that inhibit immune function should be avoided 
for long term use as far as possible. Immunomodulatory 
agents should be recommended to be used actively to treat 
immune dysfunction after severe burn injury. Immune 
globulin, colony stimulating factor, α-thymopentin, urinary 
trypsin inhibitor, and others are encouraged.[50,51]
Empirical antifungal administration[52]
For patients with host susceptive factors, antifungal 
prophylaxis should be considered.[53,54]
If  the patient’s total burn area is more than 50% TBSA, 
or full thickness burn area is more than 30% TBSA, or 
moderate to severe inhalation injury is present, or patients 
suffer from diabetes and other immune-related diseases 
before burn injury, the elderly empirical antifungals are 
recommended to start at day 7 after burn injury.
However, we need to face the risks involved in the empirical 
antifungal therapy. The fungal pathogens have demonstrated 
increasing degrees of  antifungal drug resistance.[55]
Moreover, the burn patients with following conditions 
should have empirical antifungal therapy[44]: Burn patients 
that have been applied continuously 2 kinds of  broad-
spectrum antibiotics for 5 days that cannot be stopped 
immediately; patients with deep venous or arterial catheter 
continuously for longer than 2 weeks; patients with 
trachaeostomy for longer than 2 weeks or mechanical 
ventilation for longer than 1 week; those administered 
glucocorticoids or other immunosuppressive agents for 
longer than 1 week; patients thought necessary to be given 
empirical pharmacal prevention treatment by doctors.
According to patients’ condition, the course of  empirical 
pharmacal prevention of  invasive fungal infection is advised 
for 1-2 weeks.[53]
Antifungal agents include mainly polyenes (amphotericin 
B), azoles (fluconazol, itraconazole, voriconazol) and can-
dins (caspofungin and micafungin).[56-59] For prophylaxis 
purpose, azole or candin agents are always used but not 
polyenes. Polyenes either amphotericin B or its liposome 
are the traditional classical antifungal agents, their broad-
spectrum antifungal effects are confirmed by many doctors. 
However, polyenes are used less and less at present for their 
obvious toxicity and side effects. Flucytosine is another tra-
ditional antifungal agents, but because of  its nephrotoxicity, 
it is seldom used alone to treat or prevent fungal infection.
By inhibiting the activity of  cytochrome P450-dependent 
14-α-lanosterol demethylase, alozes can impact the synthesis 
of  ergosterol, which is the main constituent of  fungal cell 
wall.[60] Candins can destroy the integrin of  the fungal cell 
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wall by inhibiting the synthesis of  1-3-β-D polyglucosan, 
which is one of  the most important components of  fungi 
wall. Consequently, the fungi are lysed.[61]
a. Pharmacal prevention by oral administration: The 
agents for oral administration include itraconazole 
oral solution, itraconazole capsules, fluconazole cap-
sules, vorionazole tablets, and so on.[58,62] The antifun-
gal spectrum of  itraconazole covers extensive range 
of  fungi, i.e. Candida, Cryptococcus, Aspergillus, 
Blastomyces dermatitidis, Coccidioides immitis, Paracoc-
cidioides, Sporotrichosis, and others. The preventive 
dose of  itraconazole oral solution or capsule is 200 mg 
once a day; the first dose should be doubled to 400 mg. 
To reduce gastrointestinal adverse effects of  itracon-
azole, the solution and capsule can be administered 
alternately during the first 3 days.[63,64] Fluconazole can 
prevent almost all kinds of  Candida, except Candida 
krusei, invasive infection. The usual preventive dose 
is 400 mg once a day.[65,66] Voriconazole is sensitive to 
almost all kinds of  Aspergilli, Cryptococcus, Candida 
including C. krusei and Candida glabrata. Moreover, 
vorionazole can prevent Dermatitis Blastomycosis, 
Coccidioidomycosis Crude Bacteria, Brazilian Cice 
Coccidioidomycosis, and Histoplasmosis Capsule. [67,68]
The common preventive dose of  vorionazole is 
200 mg, q12 h.
b. Prevention by intravenous administration: The agents 
for intravenous prevention include mainly azoles 
and candin intravenous formulation.[69,70] The usual 
preventive dosages of  azoles are 200 mg for itraconazole 
once a day; 4 mg/kg (6 mg/kg for the first loading) 
for voriconazole, Bid. To prevent the invasive fungal 
infection, candins are advised 50 mg once a day; the 
first administration of  caspofungin is 70 mg.[71]
c. Prevention by oral-intravenous sequential administra-
tion: Oral-intravenous sequential administration is rec-
ommended to prevent fungal infection. It is advised to 
give intravenous injection of  caspofungin, micafungin, 
or voriconazole for first 3-5 days for burn patients, then 
take oral application of  itraconazole, fluconazole and 
vorionazole for 1-2 weeks.
Monitoring the BIFI
For the severe burn patients at high risk, the clinical signs 
for invasive fungal infection should be monitored carefully 
every day, such as body temperature, consciousness, wound 
appearance, blood routine examination, and so on.[25]
In order to find any microbial evidences for fungal infection 
in time, microscopic examinations repeatedly are necessary. 
Various possible samples, i.e. wound secretions, sputum, 
midstream urine alveolar irrigating solution should be 
checked promptly under microscope. Meanwhile, above-
mentioned and blood samples should be cultured and the 
identified fungi should be assayed with drug-sensitive test. If  
possible, biopsy and histological check of  the tissues under 
eschar should be done continuously and repeatedly.[27,28]
For patients with possible infection, chest X-ray or/and 
computed tomography (CT) should be checked repeatedly 
to detect pulmonary infections. On the other hand, G test 
and GM test can be used repeatedly for blood and pleural 
fluid samples.[32,33]
Treatment of the BIFI
Empirical treatment
a. Adjust or stop using of  broad-spectrum antibiotics: 
Once the burn patients are suspected of  invasive fungal 
infection, it is necessary to stop using the broad-spectrum 
antibiotics immediately. If  the patient is proven to be 
complicated with bacterial infection simultaneously, 
only narrow-spectrum antibiotics can be chosen based 
on the results of  bacteriological and sensitive test.[11,43]
b. Intravenous administration of  antifungal agents: 
Vorionazole, 4 mg/kg (6 mg/kg for the first day), q12 h; 
caspofungin 50 mg once a day (70 mg for the first 
loading), the infusion time should be not less than 1 h; 
micafungin, 50 mg (100-150 mg for the first loading) once 
a day; itraconazole injection, 200 mg, q12 h for the first 
and second day, then once a day. Two weeks later, it can 
be adjusted to oral solution, 200 mg once a day.[72,73]
Wound treatment
Some antifungal agents that are not applied systemically 
can be used on wound topically to prevent invasive 
fungal infection. Either 3-5% clotrimazole cream, 
10-40% clotrimazole in dimethyl sulfoxide or 100000 
U/ml nystatin suspensions can be utilized on wound 
locally to prevent various fungi colonization, growth, and 
proliferation. A 1% ketoconazole cream or suspension 
2-3 times a day is helpful to prevent Candida or Aspergillus 
infection on wound.
Immunotherapy
Immunotherapy agents include granulocyte colony-
stimulating factor (G-CSF), granulocyte-macrophage 
colony-stimulating factor (GM-CSF), macrophage 
colony-stimulating factor (M-CSF), thymosin, interleukin 
hormone (interleukins), and infusion of  fresh plasma and 
granulocyte cells. These kinds of  agents can improve the 
host immune function through increasing the numbers 
and activities of  neutrophils and macrophages, which 
is helpful to prevent and treat the invasive fungal and 
bacterial infection.[51,74]
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Preemptive treatment
Because severe burn patients are suspected with invasive 
fungal infection by clinical manifestations, the detection 
of  fungal microorganism and sensitive test should be taken 
regularly in various samples. Before obtaining the definite 
results, preemptive treatment is advised to be applied.
 Candida tropicalis, Candida parapsilosis, and so forth are sensi-
tive to azoles and candins agents. Vorionazole, caspofungin, 
and itraconazole can be chosen for Blastomyces albicans, 
C. glabrata, or C. krusei infection. Aspergillus infection is 
suggested to be treated with vorionazole, the alternative 
treatment including candin agents, amphotericin B (except 
of  Aspergillus terreus), and itraconazole. Amphotericin B is 
recommended for Zygomycetes (Mucor) infection and com-
bined with surgical treatment is always necessary.[56,57,75,76]
Targeted treatment
Once results of  sensitivities are available, direct and special 
antifungal agents should be administered intravenously as 
soon as possible. It is suggested that the antifungal treatment 
be discontinued after manifestations of  invasive fungal 
infection have disappeared for 2-4 weeks.[53,77,78]
Surgical treatment
Once invasive fungal infection through burnt tissue is 
identified, especially Aspergillus and Mucor infection, 
the infected or suspected tissues should be removed 
immediately and resolutely. In addition to systemic loading 
by venous, the sensitive antifungal agents are recommended 
to be administered around the debrided tissues topically.[24,79]
Following complete removal of infected tissue, the wound can 
be closed by autograft, alloskin, or xenoskin, artificial skin 
transplantation. Where infected tissue may not be removed, 
exposure or semi-exposure method of  wound closure is 
recommended with the treated wound kept clean and dry.[80,81]
Summary
This guideline consisted of four parts including the concept, 
the diagnosis, the prophylaxis, and the treatment of BIFI. The 
part of concept defined the BIFI. The part of diagnosis clarified 
the standards to diagnose BIFI. In the part of prophylaxis, the 
key points for prevention of BIFI were stated in detail. The 
treatment of BIFI in the treatment part is expounded form 
four aspects, i.e. empirical treatment, preemptive treatment, 
target treatment, and surgical treatment. Generally, the whole 
guideline supplies with clues and methods, which will help 
clinician to define, diagnose, prevent, and treat the invasive 
fungal infection after burn injury.
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